Bank of New York Mellon’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Bank of New York Mellon’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,056	Closed	-$18K	–	4330
2017 Q2	$18K	Buy	+2,056	New	+$40.3K	﹤0.01%	4242
2016 Q4	–	Sell	-150	Closed	-$2K	–	4334
2016 Q3	$2K	Sell	150 -25	-14%	-$691	﹤0.01%	4262
2016 Q2	$6K	Hold	175	–	–	﹤0.01%	4307
2016 Q1	$5K	Sell	175 -20	-10%	-$535	﹤0.01%	4209
2015 Q4	$9K	Buy	195 +20	+11%	+$2.23K	﹤0.01%	4311
2015 Q3	$31K	Hold	175	–	–	﹤0.01%	4293
2015 Q2	$25K	Buy	175 +9	+5%	+$1.25K	﹤0.01%	4210
2015 Q1	$22K	Hold	166	–	–	﹤0.01%	4192
2014 Q4	$30K	Hold	166	–	–	﹤0.01%	4185
2014 Q3	$40K	Hold	166	–	–	﹤0.01%	4165
2014 Q2	$73K	Hold	166	–	–	﹤0.01%	4034
2014 Q1	$76K	Hold	166	–	–	﹤0.01%	4034
2013 Q4	$80K	Hold	166	–	–	﹤0.01%	4060
2013 Q3	$80K	Hold	166	–	–	﹤0.01%	3989
2013 Q2	$78K	Buy	+166	New	+$75.3K	﹤0.01%	3976

Other funds holding IDXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Bank of New York Mellon's IDXG Position: Q3 2017 in Review

Bank of New York Mellon sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2017, closing a stake of 2,056 shares — an estimated $18K sold.

Bank of New York Mellon first reported a position in IDXG in Q2 2013 and held it in 15 quarters. The position peaked at $80K in Q4 2013. 13 funds tracked by Wall St. Rank hold IDXG as of Q3 2017.

Bank of New York Mellon reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Bank of New York Mellon sold 2,056 Interpace Biosciences, Inc. Common Stock shares in Q3 2017, an estimated $18K.
Bank of New York Mellon first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
Bank of New York Mellon's Interpace Biosciences, Inc. Common Stock position peaked at $80K in Q4 2013.
13 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2017.

Based on Bank of New York Mellon's 13F filing for Q3 2017, filed 6 Nov 2017.